Literature DB >> 19558958

Potential clinical utility of dual time point FDG-PET for distinguishing benign from malignant lesions: implications for oncological imaging.

S Sanz-Viedma1, D A Torigian, M Parsons, S Basu, A Alavi.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19558958

Source DB:  PubMed          Journal:  Rev Esp Med Nucl        ISSN： 0212-6982


× No keyword cloud information.
  11 in total

1.  Suboptimal and inadequate quantification: an alarming crisis in medical applications of PET.

Authors:  Sandip Basu; Thomas C Kwee; Drew Torigian; Babak Saboury; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-03-18       Impact factor: 9.236

Review 2.  Defining the role of modern imaging techniques in assessing lymph nodes for metastasis in cancer: evolving contribution of PET in this setting.

Authors:  Thomas C Kwee; Sandip Basu; Drew A Torigian; Babak Saboury; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-12       Impact factor: 9.236

3.  Dual-Time-Point FDG PET/CT to Distinguish Coccidioidal Pulmonary Nodules from Those Due to Malignancy.

Authors:  Ahmed K Pasha; Travis K Walsh; Neil M Ampel
Journal:  Lung       Date:  2015-07-23       Impact factor: 2.584

Review 4.  Dynamic whole-body PET imaging: principles, potentials and applications.

Authors:  Arman Rahmim; Martin A Lodge; Nicolas A Karakatsanis; Vladimir Y Panin; Yun Zhou; Alan McMillan; Steve Cho; Habib Zaidi; Michael E Casey; Richard L Wahl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-29       Impact factor: 9.236

5.  Roles of posttherapy 18F-FDG PET/CT in patients with advanced squamous cell carcinoma of the uterine cervix receiving concurrent chemoradiotherapy.

Authors:  Feng-Yuan Liu; Tzu-Pei Su; Chun-Chieh Wang; Angel Chao; Hung-Hsueh Chou; Yu-Chen Chang; Tzu-Chen Yen; Chyong-Huey Lai
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-02-22       Impact factor: 9.236

Review 6.  Emerging role of 18F-FDG PET/CT in Castleman disease: a review.

Authors:  Benjamin Koa; Austin J Borja; Mahmoud Aly; Sayuri Padmanabhan; Joseph Tran; Vincent Zhang; Chaitanya Rojulpote; Sheila K Pierson; Mark-Avery Tamakloe; Johnson S Khor; Thomas J Werner; David C Fajgenbaum; Abass Alavi; Mona-Elisabeth Revheim
Journal:  Insights Imaging       Date:  2021-03-11

7.  18F-FDG PET during stereotactic body radiotherapy for stage I lung tumours cannot predict outcome: a pilot study.

Authors:  Erwin M Wiegman; Jan Pruim; Jan F Ubbels; Harry J M Groen; Johannes A Langendijk; Joachim Widder
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-06       Impact factor: 9.236

8.  Added Value of Dual-Time-Point 18F-FDG PET/CT With Delayed Imaging for Detecting Aortic Graft Infection: An Observational Study.

Authors:  Chih-Yung Chang; Cheng-Pei Chang; Chun-Che Shih; Bang-Hung Yang; Cheng-Yi Cheng; Chi-Wei Chang; Lee-Shing Chu; Shyh-Jen Wang; Ren-Shyan Liu
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

9.  Reproducibility of Standardized Uptake Values Including Volume Metrics Between TOF-PET-MR and TOF-PET-CT.

Authors:  Aruki Tanaka; Tetsuro Sekine; Edwin E G W Ter Voert; Konstantinos G Zeimpekis; Gaspar Delso; Felipe de Galiza Barbosa; Geoffrey Warnock; Shin-Ichiro Kumita; Patrick Veit Haibach; Martin Huellner
Journal:  Front Med (Lausanne)       Date:  2022-03-02

Review 10.  FDG PET/CT in carcinoma of unknown primary.

Authors:  Thomas C Kwee; Sandip Basu; Gang Cheng; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10-31       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.